Hypercoagulation testing in ischemic stroke

Archives of Pathology and Laboratory Medicine

Volumn 131, Issue 6, 2007, Pages 890-901

  Rahemtullah, Aliyah ^a   Van Cott, Elizabeth M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; C REACTIVE PROTEIN; CARDIOLIPIN ANTIBODY; HOMOCYSTEINE; LIPOPROTEIN A; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S; PROTHROMBIN;

ACTIVATED PROTEIN C RESISTANCE; CEREBROVASCULAR ACCIDENT; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; LABORATORY TEST; OCCLUSIVE CEREBROVASCULAR DISEASE; REVIEW; STROKE; TRANSIENT ISCHEMIC ATTACK; VEIN THROMBOSIS;

BLOOD COAGULATION TESTS; CEREBRAL VEINS; CEREBROVASCULAR ACCIDENT; HUMANS; ISCHEMIC ATTACK, TRANSIENT; PREDICTIVE VALUE OF TESTS; RECURRENCE; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 34250194027     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Review

References (141)

1. Van Cott EM, Laposata M, Prins MH. Laboratory evaluation of hypercoagulability with venous or arterial thrombosis. Arch Pathol Lab Med. 2002;126:1281-1295.
2. Van Cott EM, Laposata M. Laboratory evaluation of hypercoagulable states. Hematol Oncol Clin North Am. 1998;12:1141-1166.
3. Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med. 1996;100:530-536.
4. Brey RL, Abbott RD, Curb JD, et al. beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu heart program. Stroke. 2001;32:1701-1706.
5. Ginsburg KS, Liang MH, Newcomer L, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med. 1992;117:997-1002.
6. Ahmed E, Stegmayr B, Trifunovic J, et al. Anticardiolipin antibodies are not an independent risk factor for stroke: an incident case-referent study nested within the MONICA and Vasterbotten cohort project. Stroke. 2000;31:1289-1293.
7. Janardhan V, Wolf PA, Kase CS, et al. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and off-spring study. Stroke. 2004;35:736-741.
8. Nencini P, Baruffi MC, Abbate R, et al. Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke. 1992;23:189-193.
9. Levine SR, Salowich-Palm L, Sawaya KL, et al. IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death: a prospective cohort study. Stroke. 1997;28:1660-1665.
10. Levine SR, Brey RL, Sawaya KL, et al. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann Neurol. 1995;38:119-124.
11. Tanne D, D'Olhaberriague L, Trivedi AM, et al. Anticardiolipin antibodies and mortality in patients with ischemic stroke: a prospective follow-up study. Neuroepidemiology. 2002;21:93-99.
12. Zielinska J, Ryglewicz D, Wierzchowska E, et al. Anticardiolipin antibodies are an independent risk factor for ischemic stroke. Neurol Res. 1999;21:653-657.
13. Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. The Antiphospholipid Antibodies and Stroke Study Group (APASS). Neurology. 1997;48:91-94.
14. van Goor MP, Alblas CL, Leebeek FW, et al. Do antiphospholipid antibodies increase the long-term risk of thrombotic complications in young patients with a recent TIA or ischemic stroke? Acta Neurol Scand. 2004;109:410-415.
15. Lanthier S, Kirkham FJ, Mitchell LG, et al. Increased anticardiolipin antibody IgG titers do not predict recurrent stroke or TIA in children. Neurology. 2004;62:194-200.
16. Levine SR, Brey RL, Tilley BC, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;291:576-584.
17. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.
18. Christopher R, Nagaraja D, Dixit NS, et al. Anticardiolipin antibodies: a study in cerebral venous thrombosis. Acta Neurol Scand. 1999;99:121-124.
19. Henry J, ed. Clinical Diagnosis and Management by Laboratory Methods. 20th ed. Philadelphia, Pa: WB Saunders Co; 2001.
20. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.
21. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
22. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.
23. Rost NS, Wolf PA, Kase CS, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke. 2001;32:2575-2579.
24. Cao JJ, Thach C, Manolio TA, et al. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation. 2003;108:166-170.
25. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731-733.
26. Curb JD, Abbott RD, Rodriguez BL, et al. C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation. 2003;107:2016-2020.
27. Muir KW, Weir CJ, Alwan W, et al. C-reactive protein and outcome after ischemic stroke. Stroke. 1999;30:981-985.
28. Di Napoli M, Papa F, Bocola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke. 2001;32:133-138.
29. Arenillas JF, Alvarez-Sabin J, Molina CA, et al. C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. Stroke. 2003;34:2463-2468.
30. Winbeck K, Poppert H, Etgen T, et al. Prognostic relevance of early serial C-reactive protein measurements after first ischemic stroke. Stroke. 2002;33:2459-2464.
31. Di Napoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke. 2001;32:917-924.
32. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397.
33. Blake GJ, Ridker PM, Kuntz KM. Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels. J Am Coll Cardiol. 2002;40:49-55.
34. Di Napoli M, Papa F. Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. Stroke. 2003;34:2922-2929.
35. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64-70.
36. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959-1965.
37. Ridker PM. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation. 2003;108:2292-2297.
38. Pearson TA, Mensah GA, Alexander RW, et al. AHA/CDC Scientific Statement. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
39. Ridker PM, Manson JE, Buring JE, et al. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA. 1999;281:1817-1821.
40. Aronow WS, Ahn C, Gutstein H. Increased plasma homocysteine is an independent predictor of new atherothrombotic brain infarction in older persons. Am J Cardiol. 2000;86:585-586, A510.
41. Bostom AG, Rosenberg IH, Silbershatz H, et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med. 1999;131:352-355.
42. Bots ML, Launer LJ, Lindemans J, et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med. 1999;159:38-44.
43. Perry IJ, Refsum H, Morris RW, et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995;346:1395-1398.
44. Sacco RL, Anand K, Lee HS, et al. Homocysteine and the risk of ischemic stroke in a triethnic cohort: the NOrthern MAnhattan Study. Stroke. 2004;35:2263-2269.
45. Iso H, Moriyama Y, Sato S, et al. Serum total homocysteine concentrations and risk of stroke and its subtypes in Japanese. Circulation. 2004;109:2766-2772.
46. Moller J, Nielsen GM, Tvedegaard KC, et al. A meta-analysis of cerebrovascular disease and hyperhomocysteinaemia. Scand J Clin Lab Invest. 2000;60:491-499.
47. Fallon UB, Elwood P, Ben-Shlomo Y, et al. Homocysteine and ischaemic stroke in men: the Caerphilly study. J Epidemiol Community Health. 2001;55:91-96.
48. Stehouwer CD, Weijenberg MP, van den Berg M, et al. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year follow-up. Arterioscler Thromb Vasc Biol. 1998;18:1895-1901.
49. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346:476-483.
50. Alfthan G, Pekkanen J, Jauhiainen M, et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 1994;106:9-19.
51. Verhoef P, Hennekens CH, Malinow MR, et al. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke. 1994;25:1924-1930.
52. Boysen G, Brander T, Christensen H, et al. Homocysteine and risk of recurrent stroke. Stroke. 2003;34:1258-1261.
53. Sen S, Oppenheimer SM, Lima J, et al. Risk factors for progression of aortic atheroma in stroke and transient ischemic attack patients. Stroke. 2002;33:930-935.
54. Tanne D, Haim M, Goldbourt U, et al. Prospective study of serum homocysteine and risk of ischemic stroke among patients with preexisting coronary heart disease. Stroke. 2003;34:632-636.
55. Petri M, Roubenoff R, Dallal GE, et al. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet. 1996;348:1120-1124.
56. Lindgren A, Brattstrom L, Norrving B, et al. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke. 1995;26:795-800.
57. Meiklejohn DJ, Vickers MA, Dijkhuisen R, et al. Plasma homocysteine concentrations in the acute and convalescent periods of atherothrombotic stroke. Stroke. 2001;32:57-62.
58. Howard VJ, Sides EG, Newman GC, et al. Changes in plasma homocyst(e)ine in the acute phase after stroke. Stroke. 2002;33:473-478.
59. Gaustadnes M, Rudiger N, Moller J, et al. Thrombophilic predisposition in stroke and venous thromboembolism in Danish patients. Blood Coagul Fibrinolysis. 1999;10:251-259.
60. Press RD, Beamer N, Evans A, et al. Role of a common mutation in the homocysteine regulatory enzyme methylenetetrahydrofolate reductase in ischemic stroke. Diagn Mol Pathol. 1999;8:54-58.
61. Markus HS, Ali N, Swaminathan R, et al. A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. Stroke. 1997;28:1739-1743.
62. Salooja N, Catto A, Carter A, et al. Methylene tetrahydrofolate reductase C677T genotype and stroke. Clin Lab Haematol. 1998;20:357-361.
63. Lalouschek W, Aull S, Serles W, et al. C677T MTHFR mutation and factor V Leiden mutation in patients with TIA/minor stroke: a case-control study. Thromb Res. 1999;93:61-69.
64. Kostulas K, Crisby M, Huang WX, et al. A methylenetetrahydrofolate reductase gene polymorphism in ischaemic stroke and in carotid artery stenosis. Eur J Clin Invest. 1998;28:285-289.
65. Harmon DL, Doyle RM, Meleady R, et al. Genetic analysis of the thermolabile variant of 5, 10-methylenetetrahydrofolate reductase as a risk factor for ischemic stroke. Arterioscler Thromb Vasc Biol. 1999;19:208-211.
66. Voetsch B, Damasceno BP, Camargo EC, et al. Inherited thrombophilia as a risk factor for the development of ischemic stroke in young adults. Thromb Haemost. 2000;83:229-233.
67. De Stefano V, Chiusolo P, Paciaroni K, et al. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood. 1998;91:3562-3565.
68. Notsu Y, Nabika T, Park HY, et al. Evaluation of genetic risk factors for silent brain infarction. Stroke. 1999;30:1881-1886.
69. Topic E, Timundic AM, Ttefanovic M, et al. Polymorphism of apoprotein E (APOE), methylenetetrahydrofolate reductase (MTHFR) and paraoxonase (PON1) genes in patients with cerebrovascular disease. Clin Chem Lab Med. 2001;39:346-350.
70. Margaglione M, D'Andrea G, Giuliani N, et al. Inherited prothrombotic conditions and premature ischemic stroke: sex difference in the association with factor V Leiden. Arterioscler Thromb Vasc Biol. 1999;19:1751-1756.
71. Slooter AJ, Rosendaal FR, Tanis BC, et al. Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke. J Thromb Haemost. 2005;3:1213-1217.
72. Casas JP, Bautista LE, Smeeth L, et al. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet. 2005;365:224-232.
73. Nowak-Gottl U, Strater R, Heinecke A, et al. Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. Blood. 1999;94:3678-3682.
74. Cardo E, Monros E, Colome C, et al. Children with stroke: polymorphism of the MTHFR gene, mild hyperhomocysteinemia, and vitamin status. J Child Neurol. 2000;15:295-298.
75. Prengler M, Sturt N, Krywawych S, et al. Homozygous thermolabile variant of the methylenetetrahydrofolate reductase gene: a potential risk factor for hyperhomocysteinaemia, CVD, and stroke in childhood. Dev Med Child Neurol. 2001;43:220-225.
76. Akar N, Akar E, Ozel D, et al. Common mutations at the homocysteine metabolism pathway and pediatric stroke. Thromb Res. 2001;102:115-120.
77. McColl MD, Chalmers EA, Thomas A, et al. Factor V Leiden, prothrombin 20210G→A and the MTHFR C677T mutations in childhood stroke. Thromb Haemost. 1999;81:690-694.
78. Kenet G, Sadetzki S, Murad H, et al. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke. 2000;31:1283-1288.
79. Gunther G, Junker R, Strater R, et al. Symptomatic ischemic stroke in full-term neonates: role of acquired and genetic prothrombotic risk factors. Stroke. 2000;31:2437-2441.
80. Martinelli I, Battaglioli T, Pedotti P, et al. Hyperhomocysteinemia in cerebral vein thrombosis. Blood. 2003;102:1363-1366.
81. Boncoraglio G, Carriero MR, Chiapparini L, et al. Hyperhomocysteinemia and other thrombophilic risk factors in 26 patients with cerebral venous thrombosis. Eur J Neurol. 2004;11:405-409.
82. The VITATOPS (Vitamins to Prevent Stroke) Trial: rationale and design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke. Cerebrovasc Dis. 2002;13:120-126.
83. Clarke R. Homocysteine-lowering trials for prevention of heart disease and stroke. Semin Vasc Med. 2005;5:215-222.
84. Peterson J, Spence J. Vitamins and progression of atherosclerosis in hyperhomocyst(e)inaemia [research letter]. Lancet. 1999;351:263.
85. He K, Merchant A, Rimm EB, et al. Folate, vitamin B6, and B12 intakes in relation to risk of stroke among men. Stroke. 2004;35:169-174.
86. Al-Delaimy WK, Rexrode KM. Hu FB, et al. Folate intake and risk of stroke among women. Stroke. 2004;35:1259-1263.
87. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565-575.
88. Nguyen TT, Ellefson RD, Hodge DO, et al. Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation. 1997;96:1390-1397.
89. Ariyo AA, Thach C, Tracy R. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med. 2003;349:2108-2115.
90. Moroney JT, Tang MX, Berglund L, et al. Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA. 1999;282:254-260.
91. Ridker PM, Stampfer MJ, Hennekens CH. Plasma concentration of lipo-protein(a) and the risk of future stroke. JAMA. 1995;273:1269-1273.
92. Gaw A, Murray HM, Brown EA. Plasma lipoprotein(a) [Lp(a)] concentrations and cardiovascular events in the elderly: evidence from the prospective study of pravastatin in the elderly at risk (PROSPER). Atherosclerosis. 2005;180:381-388.
93. Rajecki M, Pajunen P, Jousilahti P, et al. Hemostatic factors as predictors of stroke and cardiovascular diseases: the FINRISK '92 Hemostasis Study. Blood Coagul Fibrinolysis, 2005;16:119-124.
94. van Kooten F, van Krimpen J, Dippel DW, et al. Lipoprotein(a) in patients with acute cerebral ischemia. Stroke. 1996;27:1231-1235.
95. Strater R, Becker S, von Eckardstein A, et al. Prospective assessment of risk factors for recurrent stroke during childhood - a 5-year follow-up study. Lancet. 2002;360:1540-1545.
96. Kargman DE, Tuck C, Berglund L, et al. Lipid and lipoprotein levels remain stable in acute ischemic stroke: the Northern Manhattan Stroke Study. Atherosclerosis. 1998;139:391-399.
97. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation. 1999;99:999-1004.
98. Coppens M, van de Poel MH, Bank I, et al. A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutation. Blood. 2006;108:2604-2607.
99. Pruissen DM, Kappelle LJ, Algra A. Polymorphisms and Risk of Ischemic Stroke (POLARIS) study: rationale and design. Eur Neurol. 2004;51:30-34.
100. Martinelli I, Franchi F, Akwan S, et al. The transition G to A at position 20210 in the 3′-untranslated region of the prothrombin gene is not associated with cerebral ischemia. Blood. 1997;90:3806.
101. Reuner KH, Ruf A, Grau A, et al. Prothrombin gene G20210→A transition is a risk factor for cerebral venous thrombosis. Stroke. 1998;29:1765-1769.
102. Corral J, Gonzalez-Conejero R, Lozano ML, et al. The venous thrombosis risk factor 20210 A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease. Br J Haematol. 1997;99:304-307.
103. Smiles AM, Jenny NS, Tang Z, et al. No association of plasma prothrombin concentration or the G20210A mutation with incident cardiovascular disease: results from the Cardiovascular Health Study. Thromb Haemost. 2002;87:614-621.
104. Santamaria A, Oliver A, Borrell M, et al. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels. Stroke. 2003;34:2387-2391.
105. Longstreth WT Jr, Rosendaal FR, Siscovick DS, et al. Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A). Stroke. 1998;29:577-580.
106. Madonna P, de Stefano V, Coppola A, et al. Hyperhomocysteinemia and other inherited prothrombotic conditions in young adults with a history of ischemic stroke. Stroke. 2002;33:51-56.
107. Aznar J, Mira Y, Vaya A, et al. Factor V Leiden and prothrombin G20210A mutations in young adults with cryptogenic ischemic stroke. Thromb Haemost. 2004;91:1031-1034.
108. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J. 2003;146:948-957.
109. Casas JP, Hingorani AD, Bautista LE, et al. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. Arch Neurol. 2004;61:1652-1661.
110. Bonduel M, Sciuccati G, Hepner M, et al. Factor V Leiden and prothrombin gene G20210A mutation in children with cerebral thromboembolism. Am J Hematol. 2003;73:81-86.
111. Barreirinho S, Ferro A, Santos M, et al. Inherited and acquired risk factors and their combined effects in pediatric stroke. Pediatr Neurol. 2003;28:134-138.
112. Haywood S, Liesner R, Pindora S, et al. Thrombophilia and first arterial ischaemic stroke: a systematic review. Arch Dis Child. 2005;90:402-405.
113. Mercuri E, Cowan F, Gupte G, et al. Prothrombotic disorders and abnormal neurodevelopmental outcome in infants with neonatal cerebral infarction. Pediatrics. 2001;107:1400-1404.
114. Martinelli I, Sacchi E, Landi G, et al. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med. 1998;338:1793-1797.
115. Gadelha T, Andre C, Juca AA, et al. Prothrombin 20210A and oral contraceptive use as risk factors for cerebral venous thrombosis. Cerebrovasc Dis. 2005;19:49-52.
116. Rodrigues CA, Rocha LK, Morelli VM, et al. Prothrombin G20210A mutation, and not factor V Leiden mutation, is a risk factor for cerebral venous thrombosis in Brazilian patients. J Thromb Haemost. 2004;2:1211-1212.
117. Tufano A, Coppola A, Varricchione N, et al. Predisposing factors in patients with early-onset cerebral vein thrombosis. Thromb Res. 2005;115:439-440.
118. Ventura P, Cobelli M, Marietta M, et al. Hyperhomocysteinemia and other newly recognized inherited coagulation disorders (factor V Leiden and prothrombin gene mutation) in patients with idiopathic cerebral vein thrombosis. Cerebrovasc Dis. 2004;17:153-159.
119. Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332:912-917.
120. Cushman M, Rosendaal FR, Psaty BM, et al. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: results from the Cardiovascular Health Study. Thromb Haemost. 1998;79:912-915.
121. Feinberg WM, Pearce LA, Hart RG, et al. Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study. Stroke. 1999;30:2547-2553.
122. Juul K, Tybjaerg-Hansen A, Steffensen R, et al. Factor V Leiden: the Copenhagen City Heart Study and 2 meta-analyses. Blood. 2002;100:3-10.
123. Catto A, Carter A, Ireland H, et al. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb Vasc Biol. 1995;15:783-785.
124. Nabavi DG, Junker R, Wolff E, et al. Prevalence of factor V Leiden mutation in young adults with cerebral ischaemia: a case-control study on 225 patients. J Neurol. 1998;245:653-658.
125. Szolnoki Z, Somogyvari F, Kondacs A, et al. Evaluation of the modifying effects of unfavourable genotypes on classical clinical risk factors for ischaemic stroke. J Neurol Neurosurg Psychiatry. 2003;74:1615-1620.
126. Duran R, Biner B, Demir M, et al. Factor V Leiden mutation and other thrombophilia markers in childhood ischemic stroke. Clin Appl Thromb Hemost. 2005;11:83-88.
127. Ganesan V, McShane MA, Liesner R, et al. Inherited prothrombotic states and ischaemic stroke in childhood. J Neurol Neurosurg Psychiatry 1998;65:508-511.
128. Martinelli I, Landi G, Merati G, et al. Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost. 1996;75:393-394.
129. Zuber M, Toulon P, Marnet L, et al. Factor V Leiden mutation in cerebral venous thrombosis. Stroke. 1996;27:1721-1723.
130. Ludemann P, Nabavi DC, Junker R, et al. Factor V Leiden mutation is a risk factor for cerebral venous thrombosis: a case-control study of 55 patients. Stroke. 1998;29:2507-2510.
131. Folsom AR, Rosamond WD, Shahar E, et al. Prospective study of markers of hemostatic function with risk of ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation. 1999;100:736-742.
132. Knuiman MW, Folsom AR, Chambless LE, et al. Association of hemostatic variables with MRI-detected cerebral abnormalities: the Atherosclerosis Risk in Communities Study. Neuroepidemiology 2001;20:96-104.
133. Sakata T, Kario K, Katayama Y, et al. Studies on congenital protein C deficiency in Japanese: prevalence, genetic analysis, and relevance to the onset of arterial occlusive diseases. Semin Thromb Hemost. 2000;26:11-16.
134. Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood. 1998;92:2353-2358.
135. Douay X, Lucas C, Caron C, et al. Antithrombin, protein C and protein S levels in 127 consecutive voung adults with ischemic stroke. Acta Neurol Scand. 1998;98:124-127.
136. Munts AG, van Genderen PJ, Dippel DW, et al. Coagulation disorders in young adults with acute cerebral ischacmia. J Neurol. 1998;245:21-25.
137. Kennedy CR, Warner G, Kai M, et al. Protein C deficiency and stroke in early life. Dev Med Child Neurol. 1995;37:723-730.
138. Bonduel M, Sciuccati G, Hepner M, et al. Prethrombotic disorders in children with arterial ischemic stroke and sinovenous thrombosis. Arch Neurol. 1999;56:967-971.
139. Strater R, Vielhaber H, Kassenbohmer R, et al. Genetic risk factors of thrombophilia in ischaemic childhood stroke of cardiac origin: a prospective ESPED survey. Eur J Pediatr. 1999;158(suppl 3):S122-125.
140. Heller C, Becker S, Scharrer I, et al. Prothrombotic risk factors in childhood stroke and venous thrombosis. Eur J Pediatr. 1999;158(suppl 3):S117-121.
141. Pohl C, Harbrecht U, Greinacher A, et al. Neurologic complications in immune-mediated heparin-induced thrombocytopenia. Neurology. 2000;54:1240-1245.